Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd.

This study tests a new drug called SSGJ-627 in 288 adults with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if it safely controls symptoms like bleeding and diarrhea. Participants must have tried other treatments without success.

This early-stage trial tests an investigational drug called SSGJ-716, given as an injection, to see if it is safe and tolerable. The study first enrolls healthy adults to test a single dose, then moves to people with moderate-to-severe atopic dermatitis (a type of eczema) who rec…

This Phase 3 trial tests a new drug called 610 in 480 Chinese adults with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. Participants receive either 610 or a placebo injection for 52 weeks. The main goal is to see if 610 reduces t…

This Phase 3 trial tests an experimental drug called 608 in 500 adults with active ankylosing spondylitis (AS), a type of arthritis that causes back pain and stiffness. Participants receive either 608 injections or a placebo. The main goal is to see if 608 improves symptoms like …

This study tests an experimental drug called SSGJ-626, an antibody that targets a protein on certain immune cells, in people with systemic lupus erythematosus (SLE). The trial will enroll 198 adults aged 18-70 with SLE. Participants will receive either the drug or a placebo as a …

This Phase 3 trial tests whether the experimental drug 611 can reduce moderate to severe COPD flare-ups in Chinese adults aged 40-85 with moderate to severe COPD. About 594 participants will receive either 611 or a placebo injection every two weeks. The study measures how often f…

This Phase 3 trial tests a drug called 611 in 180 Chinese teenagers (ages 12–17) with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. Participants receive injections every two weeks for up to a year. The main go…